Results 31 to 40 of about 21,386 (303)

Characteristics and outcomes of KSHV-associated multicentric Castleman disease with or without other KSHV diseases.

Blood Advances, 2021
Kaposi sarcoma (KS)-associated herpesvirus (KSHV)-associated multicentric Castleman disease (MCD) is a relapsing and remitting systemic lymphoproliferative disorder characterized by severe inflammatory symptoms most common among people living with HIV ...
R. Ramaswami, K. Lurain, M. Polizzotto, I. Ekwede, Kirsta Waldon, S. Steinberg, R. Mangusan, Anaida Widell, Adam W. Rupert, Jomy M. George, P. Goncalves, V. Marshall, D. Whitby, Hao-Wei Wang, S. Pittaluga, E. Jaffe, R. Little, T. Uldrick, R. Yarchoan   +18 more
semanticscholar   +1 more source

A case of acute progressive diffuse interstitial lung disease preceding idiopathic multicentric Castleman disease

Respiratory Medicine Case Reports, 2020
It has been considered that idiopathic multicentric Castleman disease often involves pulmonary complications recognized as lymphocytic interstitial pneumonia.
Daijiro Nabeya, Yuki Yoshimatsu, Hiroshi Fujiwara   +2 more
doaj   +1 more source

Treatment consistent with idiopathic multicentric Castleman disease guidelines is associated with improved outcomes

Blood Advances, 2023
Key Points • Fifty-two percent of patients with iMCD treated with siltuximab with/without corticosteroids achieved response.• Corticosteroids alone are not effective in iMCD symptom management.
S. Pierson, M. Lim, G. Srkalović, Joshua D. Brandstadter, Mateo Sarmiento Bustamante, Saishravan Shyamsundar, Natalie A Mango, C. Lavery, Bridget Austin, D. Alapat, M. Lechowicz, A. Bagg, Honzhe Li, C. Casper, F. van Rhee, D. Fajgenbaum   +15 more
semanticscholar   +1 more source

Efficacy and safety of regimens used for the treatment of multicentric Castleman disease: A systematic review

European Journal of Haematology, 2022
Treatment options for multicentric Castleman disease (MCD) remain limited. The only FDA‐approved drug is siltuximab for idiopathic MCD (iMCD), but the response rate with siltuximab is less than 50%.
M. Rehman, Asmi Chattaraj, Karun Neupane, Abdul Rafae, Sajeel Saeed, J. Basit, A. Ibrahim, Jack Khouri, S. Mukherjee, F. Anwer   +9 more
semanticscholar   +1 more source

Abdominal unicentric Castleman´s disease: a case report

The Pan African Medical Journal, 2021
Castleman´s disease is a rare disease characterized by benign lymphoepithelial proliferation. There are two forms: unicentric and multicentric Castleman´s disease. Mediastinal location is the most frequent.
Samir Bradai, Amal Khsiba, Abdelwaheb Nakhli, Moufida Mahmoudi, Asma Ben Mohamed, Abir Chaabane, Emna Chelbi, Medhioub Mona, Lamine Hamzaoui, Mousadek Azouz   +9 more
doaj   +1 more source

A novel approach for characterization of KSHV‐associated multicentric Castleman disease from effusions

British Journal of Haematology, 2022
A biopsy of lymphoid tissue is currently required to diagnose Kaposi sarcoma‐associated herpesvirus (KSHV)‐associated multicentric Castleman disease (KSHV–MCD).
Ting Zhou, C. Yuan, K. Lurain, Clarissa Rous, L. Weaver, M. Raffeld, M. Stetler-Stevenson, T. Uldrick, A. Filie, S. Pittaluga, E. Jaffe, V. Marshall, Kyle Moore, D. Whitby, R. Ramaswami, R. Yarchoan, Hao-Wei Wang   +16 more
semanticscholar   +1 more source

Incidentally detected Castleman disease in a patient with allergic rhinosinu sitis [PDF]

Srpski Arhiv za Celokupno Lekarstvo, 2008
INTRODUCTION Castleman disease was for the first time described in 1956 as a mediastinal tumour mass. Etiology of this disease is still unknown. The disease can be solitary and multicentric or rarely of a mixed type.
Stojšić Jelena, Krstić Svetlana, Subotić Dragan, Eminović Tatjana, Radojičić Jelena   +4 more
doaj   +1 more source

Multicentric Castleman Disease: A Case Report of an Arab Female. [PDF]

Cureus
Mansour MK, Zayat AS.
europepmc   +3 more sources

Dynamics of Serum Cytokines and Chemokines in Patients With Idiopathic Multicentric Castleman Disease: From a Phase Ib Investigator-Initiated Trial of Filgotinib. [PDF]

Cureus
Fukui S, Sumiyoshi R, Koga T, Hosogaya N, Narita S, Morimoto S, Yano H, Katsube A, Yano S, Masaki Y, Tsunoda S, Sato S, Migita K, Kawakami A.   +13 more
europepmc   +2 more sources

Siltuximab-Related Favorable Clinical Outcome for a Patient Suffering from Idiopathic Multicentric Castleman Disease

Case Reports in Hematology, 2022
RationalCastleman disease is a rare lymphoproliferative disorder that can be subdivided into unicentric and multicentric forms, the latter of which causes a spectrum of serious medical conditions.
Stamatios Chrysochoou, Andreas Kreft, Eberhard Schneider   +2 more
doaj   +1 more source